Connecticut Wealth Management LLC Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Connecticut Wealth Management LLC lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,782 shares of the biopharmaceutical company's stock after selling 13,000 shares during the quarter. Connecticut Wealth Management LLC's holdings in TG Therapeutics were worth $445,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after acquiring an additional 209,190 shares during the period. Soleus Capital Management L.P. grew its holdings in shares of TG Therapeutics by 5.8% during the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock worth $80,705,000 after purchasing an additional 146,702 shares in the last quarter. Clearbridge Investments LLC bought a new position in TG Therapeutics in the 4th quarter valued at about $55,237,000. Northern Trust Corp boosted its holdings in shares of TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after purchasing an additional 120,785 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock worth $38,212,000 after acquiring an additional 84,904 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Price Performance

Shares of TGTX traded up $0.61 during trading hours on Tuesday, reaching $35.18. 944,493 shares of the company's stock traded hands, compared to its average volume of 2,983,067. The firm's 50 day simple moving average is $37.98 and its 200-day simple moving average is $34.36. The stock has a market cap of $5.59 billion, a PE ratio of -351.80 and a beta of 2.21. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company's revenue was up 90.4% on a year-over-year basis. During the same period last year, the firm posted ($0.07) EPS. Equities analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

TGTX has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.